Merck KGaA (MKGAF) recently reported disappointing interim data from a late-stage study (PETACC-8) on Erbitux (cetuximab), which is being evaluated as an adjuvant treatment of stage III colon cancer. The data did not support the use of the drug for the aforementioned indication.
Results from the study, a multinational European trial, revealed that Erbitux when given in combination with standard chemotherapy (FOLFOX 4) did not prolong the disease free survival of patients, as compared to those … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards